c-KIT inhibitors reduce pathology and improve behavior in the Tg(SwDI) model of Alzheimer’s disease
Life Science Alliance · 2024
DOI: 10.26508/lsa.202402625 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2024. Verfasst von Max Stevenson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Was…. Hauptthemen laut MEDLINE: Alzheimer Disease, Mice, Transgenic, Disease Models, Animal, Proto-Oncogene Proteins c-kit. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCATS NIH HHS, Georgetown University.
Themen: Demenz
Abstract (Originalsprache)
Treatments for Alzheimer’s disease have primarily focused on removing brain amyloid plaques to improve cognitive outcomes in patients. We developed small compounds, known as BK40143 and BK40197, and we hypothesize that these drugs alleviate microglial-mediated neuroinflammation and induce autophagic clearance of neurotoxic proteins to improve behavior in models of neurodegeneration. Specificity binding assays of BK40143 and BK40197 showed primary binding to c-KIT/Platelet Derived Growth Factor Receptors (PDGFR)α/β, whereas BK40197 also differentially binds to FYVE finger-containing phosphoinositide kinase (PIKFYVE). Both compounds penetrate the CNS, and treatment with these drugs inhibited the maturation of peripheral mast cells in transgenic mice, correlating with cognitive improvements on measures of memory and anxiety. In the brain, microglial activation was profoundly attenuated and amyloid-beta and tau were reduced via autophagy. Multi-kinase inhibition, including c-KIT, exerts multifunctional effects to reduce neurodegenerative pathology via autophagy and microglial activity and may represent a potential therapeutic option for neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington DC, USA.
- Medicinal Chemistry Shared Resource, Department of Chemistry, Georgetown University Medical Center, Washington DC, USA.
- Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington DC, USA cem46@georgetown.edu.
ORCID-Profile: Charbel Moussa
Förderung
- NINDS NIH HHS
- NCATS NIH HHS
- Georgetown University
- National Center for Advancing Translational Sciences
Zitieren
APA
Stevenson, M., Hebron, M. L., Liu, X., Balaraman, K., Wolf, C., & Moussa, C. (2024). c-KIT inhibitors reduce pathology and improve behavior in the Tg(SwDI) model of Alzheimer’s disease. Life Science Alliance. https://doi.org/10.26508/lsa.202402625
Vancouver
Stevenson M, Hebron ML, Liu X, Balaraman K, Wolf C, Moussa C. c-KIT inhibitors reduce pathology and improve behavior in the Tg(SwDI) model of Alzheimer’s disease. Life Science Alliance. 2024. doi:10.26508/lsa.202402625
BibTeX
@article{Stevenson2024,
author = {Stevenson, Max and Hebron, Michaeline L and Liu, Xiaoguang and Balaraman, Kaluvu and Wolf, Christian and Moussa, Charbel},
title = {c-KIT inhibitors reduce pathology and improve behavior in the Tg(SwDI) model of Alzheimer’s disease},
journal = {Life Science Alliance},
year = {2024},
doi = {10.26508/lsa.202402625}
}
EUVIMED